Core Viewpoint - The company Youzhiyou Biotech-B (02496.HK) announced the publication of clinical trial results for its dual-target bispecific antibody drug M701, which targets EpCAM and CD3, in the treatment of malignant ascites caused by advanced epithelial tumors, marking international recognition of its innovative therapy [1] Group 1: Clinical Trial Results - The Phase II study aimed to evaluate the efficacy and safety of M701 administered via intraperitoneal infusion in patients with moderate to large malignant ascites due to advanced epithelial tumors [1] - A total of 84 patients were enrolled in the study, with 43 patients assigned to the M701 group receiving intraperitoneal infusion after paracentesis [1] - The median puncture-free survival time for the M701 group was 75 days, compared to 25 days for the control group, showing a significant difference (p=0.0065) [1] Group 2: Efficacy Across Cancer Types - Subgroup analysis indicated that various cancer types, including gastric cancer, colorectal cancer, and ovarian cancer, benefited from M701 infusion [1] - Patients with a baseline relative lymphocyte count of ≥13% experienced better efficacy [1] - The overall survival time for patients in the M701 group was extended compared to the control group, with 6-month survival rates of 33.3% for the M701 group versus 12.1% for the control group [1] Group 3: Safety Profile - No serious adverse events were observed in the M701 group during the study [1]
友芝友生物-B(02496.HK)：于《实验血液学与肿瘤学》上发表M701恶性腹水II期数据